Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 3
2004 3
2005 1
2006 1
2007 1
2008 3
2010 1
2011 2
2012 4
2013 1
2014 3
2015 3
2016 3
2017 7
2018 3
2019 6
2020 2
2021 3
2022 3
2023 2
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Results by year

Filters applied: . Clear all
Page 1
Concurrent administration of serotonergic antidepressants and ozanimod in participants with relapsing multiple sclerosis from the open-label extension DAYBREAK trial.
Naismith RT, Cohen JA, Bar-Or A, Comi G, Selmaj KW, Hartung HP, Sheffield JK, Krakovich A, Tatosian D, Cheng CY, Reardon J, Khaychuk V, Riolo JV, Silva D, Cree BA. Naismith RT, et al. Among authors: selmaj kw. Mult Scler. 2024 Feb;30(2):177-183. doi: 10.1177/13524585231216854. Epub 2023 Dec 21. Mult Scler. 2024. PMID: 38130041 Free PMC article.
Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies.
Dayan CM, Lecumberri B, Muller I, Ganesananthan S, Hunter SF, Selmaj KW, Hartung HP, Havrdova EK, LaGanke CC, Ziemssen T, Van Wijmeersch B, Meuth SG, Margolin DH, Poole EM, Baker DP, Senior PA. Dayan CM, et al. Among authors: selmaj kw. Mult Scler J Exp Transl Clin. 2023 Jan 3;9(1):20552173221142741. doi: 10.1177/20552173221142741. eCollection 2023 Jan-Mar. Mult Scler J Exp Transl Clin. 2023. PMID: 36619856 Free PMC article.
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.
Cree BA, Selmaj KW, Steinman L, Comi G, Bar-Or A, Arnold DL, Hartung HP, Montalbán X, Havrdová EK, Sheffield JK, Minton N, Cheng CY, Silva D, Kappos L, Cohen JA. Cree BA, et al. Among authors: selmaj kw. Mult Scler. 2022 Oct;28(12):1944-1962. doi: 10.1177/13524585221102584. Epub 2022 Jun 28. Mult Scler. 2022. PMID: 35765217 Free PMC article. Clinical Trial.
Fluid phase biomarkers in multiple sclerosis.
Selmaj KW, Mycko MP, Furlan R, Rejdak K. Selmaj KW, et al. Curr Opin Neurol. 2022 Jun 1;35(3):286-292. doi: 10.1097/WCO.0000000000001058. Curr Opin Neurol. 2022. PMID: 35674070 Review.
Multiple Sclerosis: circRNA Profile Defined Reveals Links to B-Cell Function.
Zurawska AE, Mycko MP, Selmaj I, Raine CS, Selmaj KW. Zurawska AE, et al. Among authors: selmaj kw. Neurol Neuroimmunol Neuroinflamm. 2021 Aug 12;8(5):e1041. doi: 10.1212/NXI.0000000000001041. Print 2021 Sep. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 34385287 Free PMC article.
Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial.
Coles AJ, Arnold DL, Bass AD, Boster AL, Compston DAS, Fernández Ó, Havrdová EK, Nakamura K, Traboulsee A, Ziemssen T, Jacobs A, Margolin DH, Huang X, Daizadeh N, Chirieac MC, Selmaj KW. Coles AJ, et al. Among authors: selmaj kw. Ther Adv Neurol Disord. 2021 Apr 23;14:1756286420982134. doi: 10.1177/1756286420982134. eCollection 2021. Ther Adv Neurol Disord. 2021. PMID: 34035833 Free PMC article.
52 results